Franz von Nussbaum

3.5k citations

59 papers · 2.0k indexed · 1 hit paper · h-index 23

Pharmacology top 2%
- Microbial Natural Products and Biosynthesis 16
Organic Chemistry top 2%
- Chemical synthesis and alkaloids 5
Molecular Medicine top 5%
- Antibiotic Resistance in Bacteria 7
Biotechnology top 5%
Molecular Biology top 10%
- PI3K/AKT/mTOR signaling in cancer 5
- Ubiquitin and proteasome pathways 4
Oncology
- Cancer-related Molecular Pathways 11
Cell Biology
- Microtubule and mitosis dynamics 6
Cancer Research
- Protease and Inhibitor Mechanisms 4

Co-authors: Dieter Häbich Michael Brands Stefan Weigand Berthold Hinzen Samuel J. Danishefsky Dominik Mumberg Wölfgang Steglich Gerhard Siemeister
Cited by: Pharmacology Organic Chemistry Molecular Medicine
Journals: Angewandte Chemie International Edition (10 papers)Cancer Research (13 papers)Clinical Cancer Research (1 paper)
Partner nations: Germany United States France

In The Last Decade

Franz von Nussbaum

58 papers receiving 2.0k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Franz von Nussbaum

Since Specialization

Citations

This map shows the geographic impact of Franz von Nussbaum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Franz von Nussbaum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Franz von Nussbaum more than expected).

Fields of papers citing papers by Franz von Nussbaum

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Franz von Nussbaum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Franz von Nussbaum. The network helps show where Franz von Nussbaum may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Franz von Nussbaum, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Franz von Nussbaum Line = papers co-authored together Franz von Nussbaum links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models Cellular Oncology ·Clara Lemos,Volker Schulze,Simon J. Baumgart,Ekaterina Nevedomskaya,Tobias Heinrich,Julien Lefranc,Benjamin Bader,Clara D. Christ,Hans Briem,Lara Kuhnke,Simon J. Holton,Ulf Bömer,Philip Lienau,Franz von Nussbaum,Carl F. Nising,Marcus Bauser,Andrea Hägebarth,Dominik Mumberg,Bernard Haendler	2021	29
2	The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models Molecular Cancer Therapeutics ·Antje M. Wengner,Gerhard Siemeister,Ulrich Lücking,Julien Lefranc,Lars Wortmann,Philip Lienau,Benjamin Bader,Ulf Bömer,Dieter Moosmayer,Uwe Eberspächer,Sven Golfier,Christoph A. Schatz,Simon J. Baumgart,Bernard Haendler,Pascale Lejeune,Andreas Schlicker,Franz von Nussbaum,Michael Brands,Karl Ziegelbauer,Dominik Mumberg	2019	145
3	Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo Clinical Cancer Research ·Gerhard Siemeister,Anne Mengel,Amaury E. Fernández‐Montalván,Wilhelm Bone,Jens Schröder,Sabine Zitzmann-Kolbe,Hans Briem,Stefan Prechtl,Simon J. Holton,Ursula Mönning,Oliver von Ahsen,Sandra Johanssen,Arwed Cleve,Vera Pütter,Marion Hitchcock,Franz von Nussbaum,Michael Brands,Karl Ziegelbauer,Dominik Mumberg	2018	53
4	BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity Cancer Letters ·Susann Santag,Franziska Siegel,Antje M. Wengner,Claudia Lange,Ulf Bömer,Knut Eis,Florian Pühler,Philip Lienau,Linda Bergemann,Martin Michels,Franz von Nussbaum,Dominik Mumberg,Kirstin Petersen	2017	48
5	Abstract 983: Identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models Cancer Research ·Ulrich Luecking,Julien Lefranc,Antje M. Wengner,Lars Wortmann,Hans Schick,Hans Briem,Gerhard Siemeister,Philip Lienau,Christoph A. Schatz,Benjamin Bader,Gesa Deeg,Franz von Nussbaum,Michael Brands,Dominik Mumberg,Karl Ziegelbauer	2017	12
6	Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity Molecular Cancer Therapeutics ·Antje M. Wengner,Gerhard Siemeister,Marcus Koppitz,Volker Schulze,Dirk Kosemund,Ulrich Klar,Detlef Stoeckigt,Roland Neuhaus,Philip Lienau,Benjamin Bader,Stefan Prechtl,Marian Raschke,Anna-Lena Frisk,Oliver von Ahsen,Martin Michels,Bertolt Kreft,Franz von Nussbaum,Michael Brands,Dominik Mumberg,Karl Ziegelbauer	2016	85
7	Neutrophil elastase inhibitors for the treatment of (cardio)pulmonary diseases: Into clinical testing with pre-adaptive pharmacophores Bioorganic & Medicinal Chemistry Letters ·Franz von Nussbaum,Volkhart M.‐J. Li	2015	80
8	The novel elastase inhibitor BAY 85-8501 provides a new approach in the treatment of pulmonary diseases European Respiratory Journal ·Johannes Nagelschmitz,Dorina Kaufel,Stephan Schwers,Franz von Nussbaum,Volkhart Li,Martina Delbeck,Klemens Lustig,Tiemo J. Bandel,Henrik Watz	2014	5
9	The novel elastase inhibitor BAY 85-8501: First-in-man study to evaluate safety, tolerability and pharmacokinetics in healthy male subjects European Respiratory Journal ·Johannes Nagelschmitz,Michael Becka,Dorina Kaufel,Stephan Schwers,Franz von Nussbaum,Volkhart Li,Georg Wensing	2014	2
10	Aspergillomarasmin A, ein Inhibitor bakterieller Metallo‐β‐Lactamasen vom bla _NDM ‐ und bla _VIM ‐Resistenztyp Angewandte Chemie ·Franz von Nussbaum,Guido Schiffer	2014	2
11	Coloured Artefacts Formed by Oxidation of Benzene‐1,2,4‐triol and β‐Dopa During the Extraction of Cortinarius violaceus (Agaricales) with Alcohols European Journal of Organic Chemistry ·Franz von Nussbaum,Matthias Rüth,Peter Spiteller,Tina Hübscher‐Weissert,Florian Löbermann,Κ. Polborn,Wölfgang Steglich	2011	3
12	Lost in Transcription—Inhibition of RNA Polymerase Angewandte Chemie International Edition ·Dieter Haebich,Franz von Nussbaum	2009	23
13	Structure and Total Synthesis of Lysobactin (Katanosin B) Angewandte Chemie International Edition ·Franz von Nussbaum,Sonja Anlauf,Jordi Benet‐Buchholz,Dieter Häbich,Johannes Köbberling,László Musza,J. Telser,Helga Rübsamen‐Waigmann,Nina Brunner	2007	38
14	Platensimycin, a New Antibiotic and “Superbug Challenger” from Nature. ChemInform ·Dieter Haebich,Franz von Nussbaum	2007	2
15	Platensimycin, a New Antibiotic and “Superbug Challenger” from Nature ChemMedChem ·Dieter Häbich,Franz von Nussbaum	2006	79
16	Antibacterial Natural Products in Medicinal Chemistry—Exodus or Revival?breakdown → Angewandte Chemie International Edition ·Franz von Nussbaum,Michael Brands,Berthold Hinzen,Stefan Weigand,Dieter Häbich	2006	530
17	Alkaloids from marine organisms. Part 8: Isolation of bisdemethylaaptamine and bisdemethylaaptamine-9-O-sulfate from an Indonesian Aaptos sp. marine sponge Tetrahedron ·Anthony J. Herlt,Lewis N. Mander,Wilson Rombang,Rymond J. Rumampuk,Soetijoso Soemitro,Wölfgang Steglich,Ponis Tarigan,Franz von Nussbaum	2004	25
18	Stephacidin B—A New Stage of Complexity within Prenylated Indole Alkaloids from Fungi Angewandte Chemie International Edition ·Franz von Nussbaum	2003	71
19	Alkaloids from marine organisms. Part 7: Synthesis of bisdemethylaaptamine and bisdemethyloxyaaptamine—a biomimetic approach to the aaptamines? Tetrahedron ·Franz von Nussbaum,Susanne Schumann,Wölfgang Steglich	2001	15
20	An Iron(III)-Catechol Complex as a Mushroom Pigment Angewandte Chemie International Edition ·Franz von Nussbaum,Peter Spiteller,Matthias Rüth,Wölfgang Steglich,Wanner Gerhard,Brandy Gamblin,Lorenzo Stievano,F. E. Wagner	1998	29

About Franz von Nussbaum

Franz von Nussbaum is a scholar working on Molecular Medicine, Pharmacology and Cancer Research, having authored 59 papers that have together received 2.0k indexed citations. Recurring topics across this work include Microbial Natural Products and Biosynthesis (16 papers), Cancer-related Molecular Pathways (11 papers), Antibiotic Resistance in Bacteria (7 papers), Microtubule and mitosis dynamics (6 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Chemical synthesis and alkaloids (5 papers), Ubiquitin and proteasome pathways (4 papers) and Protease and Inhibitor Mechanisms (4 papers). The work is most often cited by research in Pharmacology (490 citations), Organic Chemistry (809 citations) and Molecular Medicine (107 citations). Franz von Nussbaum has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Dieter Häbich, Michael Brands, Stefan Weigand, Berthold Hinzen, Samuel J. Danishefsky, Dominik Mumberg, Wölfgang Steglich, Gerhard Siemeister, Roderich D. Süßmuth and Philip Lienau. Their work appears in journals such as Angewandte Chemie International Edition, Cancer Research and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact